Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome
2024-515913-17-00Phase 2Completed
- Sponsor
- Sparrow Pharmaceuticals
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of clofutriben in Cushing's syndrome, Corticotropin adenoma (ACTHoma), ectopic corticotropin syndrome (ECS) and 1 more, sponsored by Sparrow Pharmaceuticals. Primary endpoint: Urinary HSD-1 ratio at Week 6. Started Oct 2024; status: completed.
02
Drugs
clofutriben
03
Conditions
Cushing's syndromeCorticotropin adenoma (ACTHoma)ectopic corticotropin syndrome (ECS)Ectopic corticotropin-releasing hormone secretion (ECRH)
Beyond the preview
Go deeper on 2024-515913-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515913-17-00.